Welcome to our dedicated page for Atrium Therapeutics news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Atrium Therapeutics stock.
Atrium Therapeutics develops RNA therapeutics designed for targeted delivery to heart tissue. The biopharmaceutical company focuses on precision cardiology programs for rare genetic cardiomyopathies, including candidates ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, and uses ligand-based targeting approaches with oligonucleotide-based therapies.
Recurring Atrium news covers RNA delivery-platform development, cardiology research collaborations, clinical and regulatory preparation, capital-structure updates and governance matters such as equity inducement grants. Company updates also include milestone activity under its global cardiovascular collaboration with Bristol Myers Squibb and public-company developments following Atrium's launch as an independent Nasdaq-listed issuer.
Avidity Biosciences, Inc. (Nasdaq: RNA) reported significant progress in Q2 2020, following its IPO on June 16, 2020, which raised $298.1 million. The company is advancing its pipeline of Antibody Oligonucleotide Conjugates (AOCs™), aiming to initiate three first-in-human studies by 2022. As of June 30, 2020, cash and cash equivalents reached $352.4 million, up from $94.6 million at the end of 2019. Collaboration revenue rose to $1.5 million in Q2 2020, compared to $0.2 million in Q2 2019. R&D expenses increased to $9.0 million, reflecting intensified research efforts.
Avidity Biosciences (Nasdaq: RNA) announced the appointment of Jae Kim, M.D., as Chief Medical Officer on July 27, 2020. Dr. Kim will oversee the expansion of Avidity's Antibody Oligonucleotide Conjugates (AOCs™) pipeline, adding his extensive experience in monoclonal antibody and oligonucleotide development. Previously, he held senior roles at Alnylam Pharmaceuticals and MyoKardia, contributing significantly to clinical developments. Avidity aims to leverage AOCs for treating serious diseases, with a focus on muscle-related disorders, through innovative RNA-targeted therapies.
Avidity Biosciences, Inc. (Nasdaq: RNA) announced the successful closing of its initial public offering, issuing 16,560,000 shares of common stock at $18.00 per share, garnering approximately $298.1 million in gross proceeds. This amount includes the full exercise of an underwriters' option for an additional 2,160,000 shares. The offering was facilitated by Cowen, SVB Leerink, Credit Suisse, and Wells Fargo Securities. Avidity is developing a new class of therapies called Antibody Oligonucleotide Conjugates, with a focus on treating serious diseases, including myotonic dystrophy type 1.